When Should You Start HRT?

Hot flashes during a meeting, repeated nighttime awakenings from sweating, or vaginal pain can be reasons to seek care. Describe how often symptoms happen and what they interrupt. The decision to use HRT should follow the likely diagnosis, your preferences, and a review of benefits and risks.

Systemic hormones can treat hot flashes and night sweats. If vaginal symptoms are the only concern, a low-dose vaginal treatment may be sufficient. The choice of treatment is therefore part of the timing discussion, especially when systemic therapy would introduce risks you do not need to take.

There is no need to endure a fixed number of months before seeking help. If symptoms are uncertain or atypical, the clinician can investigate other causes while discussing ways to relieve them.

The Menopause Society describes a generally favorable benefit-risk balance for otherwise healthy women with bothersome symptoms who are younger than 60 or within 10 years of menopause and have no contraindications. This summarizes population evidence about starting systemic treatment.

It is not a guarantee of safety for everyone in that age range. Cancer history, blood clots, cardiovascular disease, liver disease, unexplained bleeding, and other circumstances can change the decision. Estrogen route, dose, and progestogen use also matter.

NICE recommends identifying perimenopause clinically in otherwise healthy people aged 45 or older who have typical symptoms and menstrual changes. Routine estradiol, AMH, or ovarian imaging does not establish when HRT should begin. Hormone concentrations fluctuate during the transition.

FSH testing may be considered at ages 40 to 45 with suggestive symptoms, and before 40 when premature ovarian insufficiency is suspected. Hormonal contraception can make hormone tests and bleeding patterns difficult to interpret.

A clinician may order other tests for another reason, such as a blood count with heavy bleeding or thyroid tests with suggestive symptoms. These are targeted investigations, with the result interpreted alongside the history.

Premature ovarian insufficiency occurs before age 40. NICE recommends hormonal replacement, unless contraindicated, and continuing it until at least the usual age of natural menopause. This addresses the effects of early hormone loss as well as symptom relief. HRT or an appropriate combined hormonal contraceptive may be considered.

Menopause at ages 40 to 44 is considered early menopause. The treatment discussion should account for younger age, symptoms, and bone and cardiovascular health. NICE notes that the benefits and risks in this group fall between those for premature ovarian insufficiency and menopause at the usual age.

Removal of both ovaries or some cancer treatments can also change the timing and nature of hormone loss. The cause, cancer history where relevant, and need for ongoing specialist care affect treatment choices.

• Which symptoms the treatment is intended to relieve, and whether local or systemic therapy is appropriate.
• Whether a uterus is present and which progestogen will protect its lining.
• Any unusual bleeding, relevant cancer or clot history, cardiovascular or liver disease, and other medicines.
• Contraception and pregnancy possibility while ovulation may continue.
• A written schedule, instructions for missed doses, and a follow-up appointment.

Investigate unexplained bleeding

Heavy, prolonged, between-period, or postmenopausal bleeding needs assessment. It should not be assumed to be a normal transition change. HRT may later be part of the treatment plan, but the cause and appropriate regimen need to be reviewed first.

A three-month review usually assesses benefit and tolerability, with earlier contact for significant side effects. Starting HRT is the beginning of an ongoing prescribing decision; symptoms, risks, and preferences can change over time.